targeting egfr-positive nsclc with antibody-drug conjugates
Published 1 year ago • 159 plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:33
antibody-drug conjugates (adcs) in nsclc
-
3:58
antibody drug conjugates in lung cancer
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
27:03
antibody drug conjugates: the end of chemotherapy | 2023 west oncology conference
-
4:10
egfr mutations in advanced nsclc - targeted therapies in lung cancer 2023
-
2:26
exploring antibody-drug conjugates (adcs) in lung cancer
-
1:02:05
adjuvant egfr-targeted therapy as a game changer in multimodal nsclc management
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
10:59
lung cancer stage 4: egfr l858r & e709k positive after 13months of taking osimertinib-tagrisso
-
20:37
lung cancer stage 4 w/ 2 egfr mutations confirmed! tagrisso, tumor pill as treatment
-
2:53
desiree’s perspective after non-small cell lung cancer
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
2:07
targeted therapies for nsclc
-
0:43
developments in the management of egfr-mutated nsclc
-
21:03
treating breast cancer with egfr adc - antibody drug conjugates
-
43:35
maximizing the impact of egfr-targeted therapy in resectable nsclc
-
1:05:01
tackling the practicalities of antibody–drug conjugate therapy for solid tumors
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know
-
8:00
egfr tki resistance: targeting met amplification
-
1:30
emerging treatment strategies in egfr-mutant nsclc: osimertinib combinations and beyond
-
1:49
adcs for lung cancer
-
1:29:20
experts discuss antibody-drug conjugates in breast, lung, & gi cancers - https://bit.ly/3rkkvzm